Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Higher health care use before a clinically isolated syndrome with or without subsequent MS.

Marrie RA, Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Tremlett H.

Mult Scler Relat Disord. 2019 Jul 2;35:42-49. doi: 10.1016/j.msard.2019.07.002. [Epub ahead of print]

PMID:
31319354
2.

Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis.

McKay KA, Manouchehrinia A, Berrigan L, Fisk JD, Olsson T, Hillert J.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1546. [Epub ahead of print]

PMID:
31206130
3.

The validity and reliability of screening measures for depression and anxiety disorders in rheumatoid arthritis.

Hitchon CA, Zhang L, Peschken CA, Lix LM, Graff LA, Fisk JD, Patten SB, Bolton J, Sareen J, El-Gabalawy R, Marriott J, Bernstein CN, Marrie R.

Arthritis Care Res (Hoboken). 2019 Jun 14. doi: 10.1002/acr.24011. [Epub ahead of print]

PMID:
31199570
4.

Visual and Auditory fMRI Paradigms for Presurgical Language Mapping: Convergent Validity and Relationship to Individual Variables.

Omisade A, O'Grady CB, Schmidt MH, Fisk JD.

Neurol Res Int. 2019 Apr 1;2019:6728120. doi: 10.1155/2019/6728120. eCollection 2019.

5.

Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.

Marrie RA, Walker JR, Graff LA, Patten SB, Bolton JM, Marriott JJ, Fisk JD, Hitchon C, Peschken C, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Patient Educ Couns. 2019 Apr 6. pii: S0738-3991(19)30132-6. doi: 10.1016/j.pec.2019.04.007. [Epub ahead of print]

6.

The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease.

Lewis K, Marrie RA, Bernstein CN, Graff LA, Patten SB, Sareen J, Fisk JD, Bolton JM; CIHR Team in Defining the Burden and Managing the Effects of Immune-Mediated Inflammatory Disease .

Inflamm Bowel Dis. 2019 Mar 19. pii: izz045. doi: 10.1093/ibd/izz045. [Epub ahead of print]

PMID:
30888037
7.

Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia.

Hamodat H, Fisk JD, Darvesh S.

Can J Neurol Sci. 2019 Mar;46(2):174-183. doi: 10.1017/cjn.2019.6. Epub 2019 Mar 1.

PMID:
30819267
8.

Prodrome in relapsing-remitting and primary progressive multiple sclerosis.

Wijnands JMA, Zhu F, Kingwell E, Zhao Y, Evans C, Fisk JD, Marrie RA, Tremlett H.

Eur J Neurol. 2019 Jul;26(7):1032-1036. doi: 10.1111/ene.13925. Epub 2019 Mar 1.

PMID:
30714270
9.

Relationship Between DTI Metrics and Cognitive Function in Alzheimer's Disease.

Mayo CD, Garcia-Barrera MA, Mazerolle EL, Ritchie LJ, Fisk JD, Gawryluk JR; Alzheimer’s Disease Neuroimaging Initiative.

Front Aging Neurosci. 2019 Jan 9;10:436. doi: 10.3389/fnagi.2018.00436. eCollection 2018.

10.

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA, Marriott JJ, Peschken CA, Sareen J, Walker JR, Stewart SH, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Neurology. 2019 Jan 11. pii: 10.1212/WNL.0000000000006854. doi: 10.1212/WNL.0000000000006854. [Epub ahead of print]

PMID:
30635487
11.

MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis.

Wijnands JMA, Ekuma O, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H, Marrie RA.

Mult Scler Relat Disord. 2019 Feb;28:138-144. doi: 10.1016/j.msard.2018.12.030. Epub 2018 Dec 23.

PMID:
30594814
12.
13.

Diabetes and anxiety adversely affect cognition in multiple sclerosis.

Marrie RA, Patel R, Figley CR, Kornelsen J, Bolton JM, Graff L, Mazerolle EL, Marriott JJ, Bernstein CN, Fisk JD; Comorbidity and Cognition in Multiple Sclerosis (CCOMS) Study Group.

Mult Scler Relat Disord. 2019 Jan;27:164-170. doi: 10.1016/j.msard.2018.10.018. Epub 2018 Oct 23.

14.

Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.

Gasim M, Bernstein CN, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Marrie RA; CIHR team “Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease”.

Mult Scler Relat Disord. 2018 Nov;26:124-156. doi: 10.1016/j.msard.2018.09.008. Epub 2018 Sep 12.

15.

Identifying optic neuritis and transverse myelitis using administrative data.

Marrie RA, Ekuma O, Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:258-264. doi: 10.1016/j.msard.2018.08.013. Epub 2018 Aug 13.

PMID:
30144696
16.

Mining healthcare data for markers of the multiple sclerosis prodrome.

Högg T, Wijnands JMA, Kingwell E, Zhu F, Lu X, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:232-240. doi: 10.1016/j.msard.2018.08.007. Epub 2018 Aug 8.

PMID:
30121490
17.

Factors associated with perceived need for mental health care in multiple sclerosis.

Orr J, Bernstein CN, Graff LA, Patten SB, Bolton JM, Sareen J, Marriott JJ, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Mult Scler Relat Disord. 2018 Oct;25:179-185. doi: 10.1016/j.msard.2018.07.043. Epub 2018 Jul 29.

18.

Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease.

Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, Graff LA, Patten SB, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Inflamm Bowel Dis. 2019 Jan 10;25(2):360-368. doi: 10.1093/ibd/izy235.

PMID:
29986021
19.

Five years before multiple sclerosis onset: Phenotyping the prodrome.

Wijnands JM, Zhu F, Kingwell E, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Mult Scler. 2019 Jul;25(8):1092-1101. doi: 10.1177/1352458518783662. Epub 2018 Jul 6.

PMID:
29979093
20.

Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases.

Marrie RA, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Jul - Aug;53:65-72. doi: 10.1016/j.genhosppsych.2018.06.001. Epub 2018 Jun 7.

21.

The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases.

Enns MW, Bernstein CN, Kroeker K, Graff L, Walker JR, Lix LM, Hitchon CA, El-Gabalawy R, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

PLoS One. 2018 Jun 7;13(6):e0198975. doi: 10.1371/journal.pone.0198975. eCollection 2018.

22.

Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study.

McKay KA, Marrie RA, Fisk JD, Patten SB, Tremlett H.

Neuroepidemiology. 2018;51(1-2):1-10. doi: 10.1159/000488799. Epub 2018 May 15.

PMID:
29763935
23.

Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis.

Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, Leung S, Fiest KM, McKay KA, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2018 Mar-Apr;20(2):76-84. doi: 10.7224/1537-2073.2016-110.

24.

The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease.

Bernstein CN, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott J, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy068. [Epub ahead of print]

PMID:
29668911
25.

Mapping the Plasticity of the Escherichia coli Genetic Code with Orthogonal Pair-Directed Sense Codon Reassignment.

Schmitt MA, Biddle W, Fisk JD.

Biochemistry. 2018 May 15;57(19):2762-2774. doi: 10.1021/acs.biochem.8b00177. Epub 2018 Apr 27.

PMID:
29668270
26.

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1050-1056. doi: 10.1136/jnnp-2017-317493. Epub 2018 Mar 30.

PMID:
29602795
27.

Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Apr 10;90(15):e1316-e1323. doi: 10.1212/WNL.0000000000005302. Epub 2018 Mar 9.

28.

Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease.

Litster B, Bernstein CN, Graff LA, Walker JR, Fisk JD, Patten SB, Bolton JM, Sareen J, El-Gabalawy R, Marrie RA.

Inflamm Bowel Dis. 2018 Jul 12;24(8):1641-1648. doi: 10.1093/ibd/izy032.

PMID:
29522100
29.

Resting State BOLD Variability in Alzheimer's Disease: A Marker of Cognitive Decline or Cerebrovascular Status?

Scarapicchia V, Mazerolle EL, Fisk JD, Ritchie LJ, Gawryluk JR.

Front Aging Neurosci. 2018 Feb 21;10:39. doi: 10.3389/fnagi.2018.00039. eCollection 2018.

30.

Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis.

Marrie RA, Hitchon CA, Walld R, Patten SB, Bolton JM, Sareen J, Walker JR, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; Canadian Institutes of Health Research Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Arthritis Care Res (Hoboken). 2018 Jul;70(7):970-978. doi: 10.1002/acr.23539. Epub 2018 May 21.

31.

Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Mar - Apr;51:71-78. doi: 10.1016/j.genhosppsych.2018.01.003. Epub 2018 Jan 11.

PMID:
29353127
32.

Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study.

Marrie RA, Graff L, Walker JR, Fisk JD, Patten SB, Hitchon CA, Lix LM, Bolton J, Sareen J, Katz A, Berrigan LI, Marriott JJ, Singer A, El-Gabalawy R, Peschken CA, Zarychanski R, Bernstein CN.

JMIR Res Protoc. 2018 Jan 17;7(1):e15. doi: 10.2196/resprot.8794.

33.

Effects of physical comorbidities on disability progression in multiple sclerosis.

Zhang T, Tremlett H, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell T, Stadnyk K, Carruthers R, Wolfson C, Warren S, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.

34.

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis.

Marrie RA, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott JJ, Bernstein CN.

Mult Scler Relat Disord. 2018 Feb;20:9-15. doi: 10.1016/j.msard.2017.12.007. Epub 2017 Dec 16.

35.

Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

BMC Res Notes. 2017 Nov 25;10(1):619. doi: 10.1186/s13104-017-2958-1.

36.

Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, Marrie RA; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Neurology. 2017 Dec 12;89(24):2455-2461. doi: 10.1212/WNL.0000000000004716. Epub 2017 Nov 8.

37.

Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Epidemiol Psychiatr Sci. 2019 Jun;28(3):333-342. doi: 10.1017/S2045796017000579. Epub 2017 Nov 3.

PMID:
29098977
38.

Increased incidence of psychiatric disorders in immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

J Psychosom Res. 2017 Oct;101:17-23. doi: 10.1016/j.jpsychores.2017.07.015. Epub 2017 Aug 1.

39.

Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.

McKay KA, Evans C, Fisk JD, Patten SB, Fiest K, Marrie RA, Tremlett H.

Neuroepidemiology. 2017;48(3-4):124-130. doi: 10.1159/000477771. Epub 2017 Jul 7.

PMID:
28683461
40.

Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra.

Joshi N, Rolheiser TM, Fisk JD, McKelvey JR, Schoffer K, Phillips G, Armstrong M, Khan MN, Leslie RA, Rusak B, Robertson HA, Good KP.

J Neurol. 2017 Jul;264(7):1497-1505. doi: 10.1007/s00415-017-8555-3. Epub 2017 Jun 26.

PMID:
28653210
41.

Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus.

Hamodat H, Cash MK, Fisk JD, Darvesh S.

Neuropathol Appl Neurobiol. 2017 Dec;43(7):571-583. doi: 10.1111/nan.12423. Epub 2017 Jul 21.

PMID:
28644906
42.

Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.

Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Högg T, Stadnyk K, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Lancet Neurol. 2017 Jun;16(6):445-451. doi: 10.1016/S1474-4422(17)30076-5. Epub 2017 Apr 20.

PMID:
28434855
43.

Increased incidence and prevalence of psoriasis in multiple sclerosis.

Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD.

Mult Scler Relat Disord. 2017 Apr;13:81-86. doi: 10.1016/j.msard.2017.02.012. Epub 2017 Feb 20.

44.

Infection-related health care utilization among people with and without multiple sclerosis.

Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Marrie RA, Tremlett H.

Mult Scler. 2017 Oct;23(11):1506-1516. doi: 10.1177/1352458516681198. Epub 2016 Dec 21.

PMID:
28273769
45.

Longitudinal changes in microstructural white matter metrics in Alzheimer's disease.

Mayo CD, Mazerolle EL, Ritchie L, Fisk JD, Gawryluk JR; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2016 Dec 16;13:330-338. doi: 10.1016/j.nicl.2016.12.012. eCollection 2017.

46.

Hyperthermostable binding molecules on phage: Assay components for point-of-care diagnostics for active tuberculosis infection.

Zhao N, Spencer J, Schmitt MA, Fisk JD.

Anal Biochem. 2017 Mar 15;521:59-71. doi: 10.1016/j.ab.2016.12.021. Epub 2017 Jan 3.

PMID:
28062210
47.

Screening Tools for Anxiety in People with Multiple Sclerosis: A Systematic Review.

Litster B, Fiest KM, Patten SB, Fisk JD, Walker JR, Graff LA, Bolton JM, Sareen J, Marriott JJ, Berrigan LI, Bernstein CN, Zarychanski R, Singer A, Hitchon CA, Peschken CA, Marrie RA; CIHR Team “Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease”.

Int J MS Care. 2016 Nov-Dec;18(6):273-281. doi: 10.7224/1537-2073.2016-004.

48.

Modification of orthogonal tRNAs: unexpected consequences for sense codon reassignment.

Biddle W, Schmitt MA, Fisk JD.

Nucleic Acids Res. 2016 Dec 1;44(21):10042-10050. Epub 2016 Oct 23.

49.

Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis.

Marrie RA, Patten SB, Greenfield J, Svenson LW, Jette N, Tremlett H, Wolfson C, Warren S, Profetto-McGrath J, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis, Blanchard J, Caetano P, Elliott L, Yu BN, Bhan V, Svenson L.

Brain Behav. 2016 Jun 29;6(9):e00493. eCollection 2016 Sep.

50.

Simulation of the M13 life cycle I: Assembly of a genetically-structured deterministic chemical kinetic simulation.

Smeal SW, Schmitt MA, Pereira RR, Prasad A, Fisk JD.

Virology. 2017 Jan;500:259-274. doi: 10.1016/j.virol.2016.08.017. Epub 2016 Sep 16.

Supplemental Content

Support Center